Nicki Niemann, MD
Neurology · Phoenix, AZNPI 1093154072
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.5%), education and speaking fees — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 46.0% of the total. That places this record below the midpoint for neurology clinicians in AZ, where the typical reported total is $1,232.
Across 13 payments — averaging $46.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$279
- Medtronic$153
- Noctrix Health, Inc.$41
- Abbott$40
- Greenwich Biosciences, Inc.$38
- MDD US Operations, LLC$35
- plus $21 from 1 others
Across 188 payments — averaging $5682.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$591K
- AbbVie$414K
- Roche TCRC, Inc.$35K
- Amneal Pharmaceuticals LLC$27K
What the payments were for
- Speaking & faculty fees$214%
- Food & beverage$30751%
- Education$27946%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 3 | $279 |
| Medtronic | 3 | $153 |
| Noctrix Health, Inc. | 1 | $41 |
| Abbott | 2 | $40 |
| Greenwich Biosciences, Inc. | 1 | $38 |
| MDD US Operations, LLC | 2 | $35 |
| Acorda Therapeutics, Inc | 1 | $21 |
How this compares
$608 in reported general payments places this provider in the 35th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 260 | $469,105 |
| AustedoDeutetrabenazine | 38 | $424,704 |
| IngrezzaValbenazine Tosylate | 19 | $205,269 |
| InbrijaLevodopa | 31 | $144,747 |
| NuplazidPimavanserin Tartrate | 18 | $123,192 |
| NeuproRotigotine | 59 | $92,200 |
| GocovriAmantadine Hcl | 12 | $60,031 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 959 | $48,245 |
| OngentysOpicapone | 12 | $21,638 |
| Rivastigmine | 83 | $16,242 |
| MyrbetriqMirabegron | 21 | $15,183 |
| Entacapone | 55 | $14,715 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 194 | $13,602 |
| GemtesaVibegron | 24 | $13,297 |
| AmantadineAmantadine Hcl | 192 | $11,674 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $279 | $424,70438 claims |
| Acorda Therapeutics, IncInbrija | $21 | $144,74731 claims |
| MDD US Operations, LLCGocovri | $35 | $60,03112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 388 neurology providers in Arizona.
Other neurology in Phoenix
- Barry HendinPhoenix$2.3M
- Maria OspinaPhoenix$2.1M
- Suraj MuleyPhoenix$1.7M
- Eric ErossPhoenix$778K
- Steve ChungPhoenix$685K
- Marwan SabbaghPhoenix$603K
- Kerry KnievelPhoenix$509K
- Lori TravisPhoenix$406K
- Jeffrey GittPhoenix$275K
- Todd SchwedtPhoenix$273K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.